Author

Samantha Gadd

Lurie Children's HospitalORCID 0000-0001-5033-8585Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Eita UchidaiD· 2 shared Rintaro HashizumeiD· 2 shared Adam L. GreeniD· 1 shared Daichi Hagita· 1 shared Daniel Jay BratiD· 1 shared Dolores HambardzumyaniD· 1 shared Emma R.H. GoldiD· 1 shared Gabrielle LinkiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Eita UchidaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 7, 2026

YAP-TEAD-driven CPA4 promotes NF2-deficient meningioma growth

Kentaro Mineji, Katerina Petrosky, Ryosuke Otsuji…·Rintaro Hashizume

This study identifies CPA4 as a YAP-TEAD-driven effector in NF2-deficient meningioma, showing its role in tumor growth and sensitivity to TEAD inhibitors.

DOI 10.64898/2026.08.05.743013

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyPLoS ONEPeer-reviewedDec 22, 2025

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models

Yusuke Tomita, Gabrielle Link, Yi Ge…·Oren Josh Becher

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.

1 citation

mousebulk RNA-seq

𝕏 PostBluesky